Bio One

About Bio-One Corporation

Bio-One Corporation was formed to serve the emerging niche of preventive and alternative healthcare through nutritional supplements. This niche has grown to a multi-billion dollar industry. The market is considered global. The Company’s strategy is to build its business through vertical integration of manufacturing, distribution and marketing by selectively acquiring industry leaders in each distribution channel. Bio-One intends to be one of the first to launch its plan by targeting companies under $25 million in annual sales. The Company's home state, Florida, ranks first nationally in per capita consumption of nutritional supplements and second only to California in total industry sales. Bio-One's goals are threefold; 1) to serve people worldwide who desire vitality and longevity; 2) to interface a quality and value growth philosophy through the acquisition of selected businesses; 3) to provide a superior return on investment for Company shareholders

Bio-One and their advisors have developed strict criteria in targeting of the acquisition candidates. Research has revealed that 90% of the marketing companies outsource the manufacturing of their products. Approximately 40% of the marketing companies’ sales, which previously went toward their cost of goods sold, can be captured by the Bio-One owned manufacturer subsidiary, thus increasing operating profits.

Bio-One Corporation is committed to its mission of the continuing pursuit of excellence in serving our customers, our suppliers, our team members and our shareholders. Bio-One intends to accomplish its mission and goals through the application of its management philosophy, which is to treat others the way we want to be treated.

After much foundational work, management has begun our development strategy. We have acquired our first four companies, 100% of PNLabs, Inc. (www.pnlabs.com), 80% of American Nutritional Exchange, Inc. (www.americannutritional.com), 100% of Interactive Nutrition International, Inc. (www.interactivenutrition.com), and 51% of Weifang Shengtai Pharmaceuticals Co. Ltd (www.chinaglucose.com). We have also formed three new subsidiaries, Nutrition Sciences Corporation, ANI Distribution and Healthy Choices Concepts. Management anticipates that the combined revenues for year-end 2004 will approach $40 million with operating profit in the 10% range. We have three Letters of Intent signed and are in discussions with additional candidates. Upon the Closings of the aforementioned, Bio-One’s annualized revenues will approach $100 million with operating profit in the 15% range. Management has raised $21.5 million in capital, of which $6.5 million is in equity and $15 million is in a convertible debenture. We also have an equity line of $50 million. To date all funds and the equity line have come from Cornell Capital Partners (www.cornellcapital.com), a U.S. hedge fund. We are now in discussion with certain investment funds and accredited investors regarding longer-term capital. Our Management Team has been working with Health Business Partners (www.healthbusiness.com), which is the leading mergers and acquisition advisor in our industry. Their assignment is to assist in identifying additional acquisitions that would grow Bio-One revenues to $200 million annualized by the end of 2007 with operating profits in the 15% to 20% range. Future plans include applying for listing on the American Stock Exchange. Management is also considering a possible spin off of Bio-One China and applying for a separate listing on the NASDAQ. At that point, our stock would be trading on two exchanges.

 

 

 

http://www.bioonecorp.com/index.htm

 

http://finance.yahoo.com/q?s=BICO.OB

 

http://www.cohenresearch.com/reports/bico_10-11-04.pdf

 

 

 

 

Associated Press
Cerus, Baxter Intend Larger BioOne Deal
Wednesday January 5, 11:10 am ET

CONCORD, Calif. (AP) -- Cerus Corp. reported Wednesday that it and units of health-care products company Baxter International Inc. agreed to allow BioOne Corp. to commercialize their Intercept blood system for plasma products in Asia.

Cerus, which co-developed Intercept with marketing partner Baxter, received an upfront payment of $3 million for signing a letter of intent. The companies are in talks for a definitive agreement.

Cerus and Baxter received $15 million in October from BioOne to commercialize the pathogen inactivation technology in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore for platelet products. The new agreement covers plasma products in the same countries.

Shares of Cerus rose 2 cents to $3.33 in morning trading on the Nasdaq. Baxter shares rose 69 cents, or 2 percent, to $35.24 on the New York Stock Exchange.

http://www.cohenresearch.com/reports/bico_10-11-04.pdf

•  Baxter, Cerus Resolve Loan Dispute
  Thursday February 3, 2:50 pm ET

DEERFIELD, Ill. (AP) -- IV supplies maker Baxter International Inc. and Cerus Corp., a developer of blood-safety technology, said Thursday they agreed to market and develop the Intercept blood system in Europe at least through 2006, and resolved their loan dispute and related legal actions.

Under a separate agreement, Cerus will immediately pay $34.5 million to Baxter Capital Corp. and provide a promissory note for $4.5 million, payable with interest in December 2006. Baxter Capital has agreed these payments satisfy the loan obligation.

The companies said this deal doesn't change their relationship with Asian partner, BioOne Corp. In 2004, the companies announced an agreement under which BioOne would market and distribute the Intercept blood system for platelets in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore.

Baxter shares rose 34 cents to $34.31 in afternoon trading on the New York Stock Exchange. Cerus shares rose 13 cents, or 3.5 percent, to $3.90 on the Nasdaq.